Baijin Life Science (HKG:1466) expects a loss of HK$100,000 for the year ended March 31, down from HK$8.5 million a year prior, a Thursday Hong Kong bourse filing said.

The jewelry business attributed the anticipated narrowing of loss mainly to a rise in revenue and gross profit, an increase in the reversal of allowances for expected credit losses on trade and other receivables, and higher other gains.